Last reviewed · How we verify

NCT02777086: DRR2

Sustainable HIV Risk Reduction Strategies for Probationers

Completed NA Results posted Last updated 19 October 2020
What this trial tests

NA trial testing StaySafe in Health Behavior in 511 participants. Completed in 31 March 2020.

Timeline
30 September 2015
Primary endpoint
6 August 2019
31 March 2020

Quick facts

Lead sponsorTexas Christian University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment511
Start date30 September 2015
Primary completion6 August 2019
Estimated completion31 March 2020
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Texas Christian University

Who can join

18 and older, any sex, with Health Behavior. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

HIV Knowledge Confidence Primary · 3-months

Questionnaire measure of knowledge, confidence \& motivation around HIV knowledge. Values range from 10 to 50 with higher scores indicating higher knowledge, confidence \& motivation.

GroupValue95% CI
StaySafe42.9± 5.4
Comparison40.5± 7.1
Avoiding Risky Sex Primary · 3-months

Questionnaire measure of knowledge, confidence, and motivation in avoiding risky sex behaviors. Values range from 10 to 50 with higher scores indicating higher knowledge, confidence \& motivation.

GroupValue95% CI
StaySafe43.1± 5.6
Comparison41.3± 7.1
HIV Services & Testing Primary · 3-months

Questionnaire measure of knowledge, and motivation around getting tested for HIV and obtaining HIV services. Values range from 10 to 50 with higher scores indicating higher knowledge, confidence \& motivation.

GroupValue95% CI
StaySafe44.3± 5.3
Comparison42.1± 5.9
Risk Reduction Skills Primary · 3-months

Questionnaire measure of knowledge, confidence and motivation around risk reduction skills. Values range from 10 to 50 with higher scores indicating higher knowledge, confidence \& motivation.

GroupValue95% CI
StaySafe44.3± 4.7
Comparison43.0± 5.6

Sponsor's own description

The purpose of the Texas Christian University (TCU) Disease Risk Reduction (DRR2) Project is to develop and test a self-administered tablet computer app, StaySafe, for probationers under community supervision that is designed to improve decision-making skills around health risk behaviors, especially involving HIV and hepatitis B \& C risks. StaySafe utilizes materials and concepts adapted from an earlier, group-based curriculum, WaySafe, designed to increase positive decision-making skills for offenders in the last phase of their prison-based substance abuse treatment before transitioning back to the community.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. An evaluation of StaySafe, a tablet app to improve health risk decision-making among people under community supervision.
    Lehman WEK, Pankow J, Muiruri R, Joe GW, et al · · 2021 · cited 3× · PMID 34118712 · DOI 10.1016/j.jsat.2021.108480
  2. The Effectiveness of the <i>StaySafe</i> Intervention Using a Paradigm for Predicting Missing Outcome Data.
    Joe GW, Lehman WEK, Yang Y, Knight K. · · 2025 · PMID 37956984 · DOI 10.1177/01632787231212462
  3. Decision-Making Styles as a Moderator on the Efficacy of the <i>StaySafe</i> Tablet Intervention.
    Joe GW, Lehman WEK, Pankow J, Wiese A, et al · · 2023 · PMID 37184071 · DOI 10.1080/10826084.2023.2212301

Verify or expand the search:

Other recruiting trials for Health Behavior

Currently open trials in the same condition.

Other Texas Christian University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02777086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing